Breaking Down Revenue Trends: Dynavax Technologies Corporation vs BioCryst Pharmaceuticals, Inc.

Biotech Revenue Battle: Dynavax vs. BioCryst

__timestampBioCryst Pharmaceuticals, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 20141360800011032000
Thursday, January 1, 2015482570004050000
Friday, January 1, 20162635300011043000
Sunday, January 1, 201725186000327000
Monday, January 1, 2018206530008198000
Tuesday, January 1, 20194883500035219000
Wednesday, January 1, 20201781200046551000
Friday, January 1, 2021157170000439442000
Saturday, January 1, 2022270827000722683000
Sunday, January 1, 2023331412000232284000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Trends: Dynavax vs. BioCryst

In the ever-evolving landscape of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Dynavax Technologies Corporation and BioCryst Pharmaceuticals, Inc. have shown intriguing revenue trajectories. Starting in 2014, BioCryst's revenue was approximately 13.6 million, while Dynavax trailed slightly at 11 million. Fast forward to 2023, BioCryst's revenue surged by over 2300% to reach 331 million, showcasing a robust growth trajectory. Meanwhile, Dynavax experienced a remarkable peak in 2022 with a revenue of 723 million, a staggering increase from its 2014 figures, before settling at 232 million in 2023. This dynamic shift highlights the volatile yet promising nature of the biotech industry, where strategic innovations and market demands drive financial outcomes. As these companies continue to innovate, their revenue trends offer a glimpse into the future of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025